NCT01142232 · OUTCOME

Phase II: Treatment-Related Adverse Events Grade 3 or Higher

Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma · Source last updated 2019-10-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

What was measured

Number of unique patients who had a treatment-related (possible, probable or definite) adverse events that were graded 3 or higher.

Analysis population: All Phase II patients who received treatment.

All patients will receive Melphalan 100 mg/m2 intravenously day -2 and day -1 and Lenalidomide 150 mg given daily day -7 to day +2

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Phase II	44

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Phase II	18	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

denoms

description

Number of unique patients who had a treatment-related (possible, probable or definite) adverse events that were graded 3 or higher.

groups

param Type

COUNT_OF_PARTICIPANTS

population Description

All Phase II patients who received treatment.

reporting Status

POSTED

time Frame

up to 5 years

title

Phase II: Treatment-Related Adverse Events Grade 3 or Higher

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice